Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.88 - $107.37
Previous CloseN/A
Volume227.93K
Average Volume (3M)656.53K
Market Cap
$3.47B
Enterprise Value$3.99B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Mar 20, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding54,074,670
10 Day Avg. Volume500,948
30 Day Avg. Volume656,526
Standard Deviation0.21
R-Squared0.00483
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)22.30
Price to Cash Flow (P/CF)28.30
P/FCF Ratio30.60
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit36.13
Enterprise Value/Ebitda-120.35
Forecast
1Y Price Target
$115.18Price Target Upside75.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Arcellx Inc News
PremiumCompany Announcements
Arcellx, Inc. Reports Q3 2024 Earnings Highlights
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyAnito-cel is highly differentiated on safety, offering a meaningful commercial advantage with no delayed neurotoxicity cases.
Market PotentialManagement reiterated their view that iMMagine-3 could unlock a $12b total addressable market.
Product SupportA preference for anito-cel to be used across the board with all patients was noted by key opinion leaders, reflecting strong support for its broader application.
Bears Say
Adverse EventsThere are three deaths reported due to treatment-emergent adverse events, though two are likely unrelated to anito-cel.
Investor ConcernsInvestors are nervous about the potential for a case of neurotoxicity to pop up down the road.
Product DifferentiationAnito-cel is highly differentiated on safety compared to Legend/JnJ's CARVYKTI, with zero cases of delayed neurotoxicity and a lower ICANS rate.
---
Ownership Overview
3.06% Insiders
25.03% Mutual Funds
0.06% Other Institutional Investors
59.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.88 and its highest was $107.37 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $3.47B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Nov 07, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.17.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -0.55.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 54,074,670 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 3.933%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
---
Arcellx Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.18 (75.55% Upside)
$115.18 (75.55% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.09%
12-Months-Change
Fundamentals
Return on Equity
-10.79%
Trailing 12-Months
Asset Growth
24.53%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
---
ACLX Stock 12 Month Forecast
Average Price Target
$115.18
▲(75.55% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Editas Medicine
―
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+48.88%
assigned a buy rating 4 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +48.88% per trade.
---